Synthesis and biological study of a new series of 4′-demethylepipodophyllotoxin derivatives

被引:46
作者
Duca, M
Guianvarc'h, D
Meresse, P
Bertounesque, E
Dauzonne, D
Kraus-Berthier, L
Thirot, S
Léonce, S
Pierré, A
Pfeiffer, B
Renard, P
Arimondo, PB
Monneret, C
机构
[1] Inst Curie, Sect Rech, UMR 176, CNRS, F-75248 Paris 05, France
[2] CNRS, UMR 5153, Biophys Lab, Museum Natl Hist Nat,USM 0503,INSERM,UR565, F-75231 Paris 05, France
[3] Inst Rech Servier, Div Rech Cancerol, F-78290 Croissy Sur Seine, France
关键词
D O I
10.1021/jm0495733
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
Etoposide (VP-16) is a potent human DNA topoisomerase II poison, derived from 4'-de-methylepipodophyllotoxin, widely used in cancer chemotherapy. Continuous efforts have driven to synthesize new related compounds, presenting decreased toxic side effects. metabolic inactivation, drug resistance, and increased water solubility. Identified structure-activity relationships have pointed out the importance of the 4beta-substitution and of the configuration,1011 of the D ring. Here we report the synthesis of two novel series of derivatives of 4'-de-methylepipodophyllotoxin. The first bears a carbamate chain in the 4 position (13a-f): whereas. in the second series in addition to this chain, the lactone ring has been modified by shifting the carbonyl from position 13 to position 11 (27a-f). Moreover, an analogue of TOP-53 having this lactone modification has also been prepared (32). From this study, structure-activity relationships were established. Compounds 13a and 27a displayed potent cytotoxic activity against the L1210 cell line (10 to 20-fold higher than VP-16) and proved to be strong topoisomerase II poisons more potent than VP-16. From preliminary in -vivo investigation of both compounds against P388 leukemia and orthotopically grafted human A549 lung carcinoma. it appeared that 13a and 27a constitute promising leads for a new class of antitumor agents.
引用
收藏
页码:593 / 603
页数:11
相关论文
共 35 条
[1]
[Anonymous], 1988, LAB ANIM-UK, V22, P195
[2]
SYNTHETIC ANALGESICS .8. FURTHER ATTEMPTS TO PREPARE 3-PHENYLPIPERIDINE DERIVATIVES [J].
AVISON, AWD ;
MORRISON, AL .
JOURNAL OF THE CHEMICAL SOCIETY, 1950, (JUN) :1474-1477
[3]
ETOPOSIDE - CURRENT STATUS AND FUTURE PERSPECTIVES IN THE MANAGEMENT OF MALIGNANT NEOPLASMS [J].
BELANI, CP ;
DOYLE, LA ;
AISNER, J .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 :S118-S126
[4]
A two-drug model for etoposide action against human topoisomerase IIα [J].
Bromberg, KD ;
Burgin, AB ;
Osheroff, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (09) :7406-7412
[5]
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme [J].
Burden, DA ;
Osheroff, N .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :139-154
[6]
DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for drug action [J].
Byl, JAW ;
Cline, SD ;
Utsugi, T ;
Kobunai, T ;
Yamada, Y ;
Osheroff, N .
BIOCHEMISTRY, 2001, 40 (03) :712-718
[7]
DNA sequence selectivity of topoisomerases and topoisomerase poisons [J].
Capranico, G ;
Binaschi, M .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :185-194
[8]
DNA topoisomerases: Structure, function, and mechanism [J].
Champoux, JJ .
ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 :369-413
[9]
Antitumor agents .163. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethylepipodophyllotoxin analogs using the modified CoMFA/q(2)-GRS approach [J].
Cho, SJ ;
Tropsha, A ;
Suffness, M ;
Cheng, YC ;
Lee, KH .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (07) :1383-1395
[10]
Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611 [J].
Daley, L ;
Guminski, Y ;
Demerseman, P ;
Kruczynski, A ;
Etievant, C ;
Imbert, T ;
Hill, BT ;
Monneret, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (23) :4475-4485